TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Ridahpharma AB
Closing information (x1000 EUR)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
4
|
0 | |
| Financial expenses |
0
|
0 | |
| Earnings before taxes |
-22
|
154 | |
| EBITDA |
-22
|
-34 | |
| Total assets |
174
|
196 | |
| Current assets |
48
|
70 | |
| Current liabilities |
2
|
2 | |
| Equity capital |
172
|
194 | |
| - share capital |
9
|
9 | |
| Employees (average) |
2
|
0
|
0 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
98.9%
|
99.0% | |
| Turnover per employee | |||
| Profit as a percentage of turnover | -550.0% | ||
| Return on assets (ROA) |
-12.6%
|
78.6% | |
| Current ratio |
2400%
|
3500% | |
| Return on equity (ROE) |
-12.8%
|
79.4% | |
| Change turnover |
4
|
0 | |
| Change turnover % | -18% | ||
| Chg. No. of employees |
2
|
0
|
0 |
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.